Clinical Edge Journal Scan

Risk factors for progression from subclinical to clinical psoriatic arthritis


 

Key clinical point : Alcohol consumption, older age, suffering from fatty liver when less than 45 years old, and elevated high-sensitivity C-reactive protein (hs-CRP) level appear to increase the risk of transition from subclinical to clinical psoriatic arthritis (PsA).

Major finding: Older age (greater than 45 years; odds ratio [OR], 10.15; P = 0.00), alcohol consumption (OR, 3.43; P = .03), and elevated hs-CRP (OR, 1.05; P = 0.03) were associated with an increased risk of progression from subclinical PsA to clinical PsA. For patients aged less than 45 years old, the association between fatty liver and clinical PsA was statistically significant.

Study details: The data come from a retrospective case-control study of 25 patients with clinically confirmed PsA (cases) and 137 controls without confirmed PsA.

Disclosures: This study was funded by the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University, Chengdu, Sichuan, China and West China Precision Medicine Industrial Technology Institutes. The authors declared no conflicts of interest.

Source: Wang Y et al. Rheumatol Ther. 2021 Mar 5. doi: 10.1007/s40744-021-00295-y .

Recommended Reading

Methotrexate-associated hepatotoxicity risk differs between psoriasis, PsA, and RA patients
Psoriatic Arthritis ICYMI
Recent psoriasis pathophysiology insights carry treatment implications
Psoriatic Arthritis ICYMI
To improve psoriatic arthritis outcomes, address common comorbidities
Psoriatic Arthritis ICYMI
Checkpoint inhibitor–induced rheumatic complications often arise late
Psoriatic Arthritis ICYMI
FDA warning letters target OTC cannabidiol product claims for pain relief
Psoriatic Arthritis ICYMI
COVID-19 vaccination in RMD patients: Safety data “reassuring”
Psoriatic Arthritis ICYMI
Experts highlight recent breakthroughs in psoriatic arthritis
Psoriatic Arthritis ICYMI
Is pain linked to mortality risk in patients with psoriatic arthritis?
Psoriatic Arthritis ICYMI
PsA: Brodalumab demonstrates favorable efficacy in phase 3 trials
Psoriatic Arthritis ICYMI
Continuing ixekizumab superior to withdrawal in stable psoriatic arthritis
Psoriatic Arthritis ICYMI